CPI-637

An inhibitor of CBP/EP300 bromodomains

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
10mg

￥900.00

720.00

- +
50mg

￥3250.00

2600.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci5006
CAS: 1884712-47-3
别名:
分子式: C22H22N6O
分子量: 386.45
纯度: >98%
溶解度: ≥ 19.3mg/mL in DMSO with gentle warming
储存: Store at -20°C
库存: 现货

Background

IC50: 0.03 and 11.0 μM for CBP/EP300 and BRD4, respectively.

CPI-637 is a CBP/EP300 bromodomain inhibitor.

It has been reported that among bromodomain-containing proteins implicated in various disease pathways, cyclic-AMP response element binding protein (CBP) and adenoviral E1A binding protein of 300 kDa (EP300), which is a highly homologous pair of bromodomain-containing transcriptional coactivators, are of great interest as potential drug targets due to their reported involvement in a variety of disease states.

In vitro: Previous study found that CPI-637 was potent against EP300, and its opposite enantiomer showed a over 200-fold loss in potency. Moreover, the biochemical potency of CPI-637 translated well into cells with CBP BRET EC50 of 0.3 μM, and CPI-637 demonstrated a more than 700-fold selectivity over the BET family of bromodomains. In addition, CPI-637 was also highly selective against other bromodomains, showing substantial biochemical activity only against BRD9. Furthermore, it was found that CPI-637 was able to inhibit the expression of MYC with an EC50 of 0.60 μM in a cellular assay,. [1].

In vivo: So far, there is no animal in vivo data reported.

Clinical trial: Up to now, CPI-637 is still in the preclinical development stage.

Reference:
[1] Taylor, A.? M. et al. Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637). ACS medicinal chemistry letters 7, 531-536, doi:10.1021/acsmedchemlett.6b00075 (2016).